Bud and Yvonne

Diagnosed with chronic myeloid leukemia (CML), Bud noticed an article in the newspaper on Brian Druker's research. Bud and his wife Yvonne contacted Druker in 1996, and Bud was the first patient to receive the drug STI-571 (Gleevec) in clinical trials.

chronic myeloid leukemia,brian druker,drug sti,recovery thanks,gleevec,cml,yvonne,bud,leukemia,clinical trials

  • ID: 15712
  • Source: DNALC.DNAi

Related Content

15042. The first day of clinical trials for Gleevec, Bud and Yvonne

Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.

  • ID: 15712
  • Type: image
  • Source: DNAi

15056. Approval for Gleevec in record time, Brian Druker

Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.

  • ID: 15712
  • Type: image
  • Source: DNAi

15714. Brian Druker

Brian Druker is a professor at Oregon Health Sciences University.

  • ID: 15712
  • Type: image
  • Source: DNAi

15043. Bloodcount returns to normal with Gleevec, Bud and Yvonne

CML causes an increased production of white blood cells. Bud and Yvonne talk about the breakthrough that brought Bud's white blood cell count back to normal.

  • ID: 15712
  • Type: image
  • Source: DNAi

16105. The magic pills, Bud and Yvonne

Yvonne talks about the magic pills Bud took.

  • ID: 15712
  • Type: image
  • Source: DNAi

15057. Before and after Gleevec, Brian Druker

Brian Druker talks about the drug he developed as a turning point in the war on cancer.

  • ID: 15712
  • Type: image
  • Source: DNAi

15041. Getting the diagnosis of chronic myeloid leukemia, Bud

Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.

  • ID: 15712
  • Type: image
  • Source: DNAi

15054. Restoring hope with Gleevec, Brian Druker

Brian Druker talks about how Gleevec has restored patients' hope for the future.

  • ID: 15712
  • Type: image
  • Source: DNAi

15082. Shutting down cancer with Gleevec, Brian Druker

Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.

  • ID: 15712
  • Type: image
  • Source: DNAi

15055. Using DNA science to control CML, Brian Druker

Brian Druker talks about how the drug he designed targets the molecular cause of CML.

  • ID: 15712
  • Type: image
  • Source: DNAi